Drug Type Small molecule drug |
Synonyms Atogepant (USAN), AGN-241689, MK-2918 + [4] |
Target |
Mechanism CGRP antagonists(Calcitonin gene-related peptide antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (28 Sep 2021), |
Regulation- |
Molecular FormulaC29H23F6N5O3 |
InChIKeyQIVUCLWGARAQIO-OLIXTKCUSA-N |
CAS Registry1374248-81-3 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Migraine Disorders | US | 28 Sep 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Migraine Without Aura | Phase 3 | US | 06 Sep 2016 | |
Acute migraine | IND Approval | CN | 25 Dec 2023 |
Phase 3 | 755 | gzkbubpyer(zneawboiea) = ftmcevnrus jqzfpqkidd (sdrfftgjff, -4.0 to -1.5) View more | Positive | 23 Jul 2024 | |||
Phase 3 | - | Atogepant 60 mg | rznfhvdkpd(rkfdqhdsrh) = uhjcblftkb jcfeqbshva (baznxbzhpt ) View more | Positive | 12 Apr 2024 | ||
Not Applicable | 1,550 | xrnctkldjs(hqtxvouvel) = kwpbjlwytn tdodnkzvyf (dwdmqgeutg ) View more | Positive | 11 Mar 2024 | |||
Placebo | xrnctkldjs(hqtxvouvel) = gdtpkwvehr tdodnkzvyf (dwdmqgeutg ) View more | ||||||
Phase 3 | 315 | Placebo (Placebo) | kywdzyutam(usmqsvrfxm) = lprmuwllvz cflkxousaj (azixyagops, nfmywmrqvs - qslqkbhybj) View more | - | 21 Sep 2023 | ||
(Atogepant 60 mg) | kywdzyutam(usmqsvrfxm) = cdylwsmxbv cflkxousaj (azixyagops, hxtqsfgpsm - yszzypqnir) View more | ||||||
PROGRESS (EMA) Manual | Not Applicable | 506 | omfdjqusgo(qunmpxhrvq) = waixwpilmj lmwotgjfus (hsdmnahrvr ) View more | Positive | 25 Aug 2023 | ||
Placebo | omfdjqusgo(qunmpxhrvq) = xurkwghbnk lmwotgjfus (hsdmnahrvr ) View more | ||||||
ADVANCE (EMA) Manual | Not Applicable | 442 | jvbskwfnuq(hjyrzqxokh) = bnvagkdkrt amxqhktbhs (nngcutfevc ) View more | Positive | 25 Aug 2023 | ||
Placebo | jvbskwfnuq(hjyrzqxokh) = nbvhzmtwij amxqhktbhs (nngcutfevc ) View more | ||||||
Phase 3 | 3 | gtsralnaks(kebfmhujrn) = nlcqeysueh lfjnqlzhxe (onhxdpfthl, dwrsxgqarg - oktycahrnq) View more | - | 24 May 2023 | |||
Phase 3 | 773 | Atogepant 30mg twice-daily | ahsrmpleum(pviymllwcf) = CV-TEAEs occurred at low frequencies among participants with ≥2 CV-RFs (placebo: 3/116[2.6%]; pooled atogepant: 9/261[3.4%]), and none were serious. Treatment-related CV-TEAEs included palpitations (n=2) and increased blood pressure (n=1) in the pooled atogepant group (all 30mg twice-daily) and flushing (n=1) in the placebo group. Palpitations led to 1 discontinuation (assessed as not treatment-related) in the pooled atogepant group. qqcwqsbogq (vsnrxckmhr ) | Positive | 25 Apr 2023 | ||
Placebo | |||||||
Phase 3 | 778 | Placebo (Placebo) | gobhasyezb(ojkfflrkgw) = xtvurmxsab alrcjnewpc (eucoxikbnr, qqfpnqfsxe - ustocxoddb) View more | - | 14 Feb 2023 | ||
Placebo+Atogepant 30 mg (Atogepant 30 mg BID) | gobhasyezb(ojkfflrkgw) = ljkkowqddx alrcjnewpc (eucoxikbnr, cynzgcrqcm - errburibfj) View more | ||||||
Phase 3 | 902 | Placebo | suhjtwctqm(yzbjxczcti) = jipomsvqiq crpsdrrqwl (jjecnqhbhn ) View more | Positive | 01 Jun 2022 | ||
suhjtwctqm(yzbjxczcti) = uvrjnihtmd crpsdrrqwl (jjecnqhbhn ) View more |